Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer

Kumiko Karasawa, Kuniaki Katsui, Kaori Seki, Mari Kohno, Nahoko Hanyu, Sachiko Nasu, Hiroyuki Muramatsu, Katsuya Maebayashi, Norio Mitsuhashi, Shunsuke Haga, Tsunehito Kimura, Isamu Takahashi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Docetaxel has shown remarkable radiosensitizing properties in vitro. In this study we investigated whether the addition of docetaxel to radiotherapy enhanced tumor response in patients with advanced or recurrent breast cancer. Methods: A total of 35 patients were enrolled in this study. Docetaxel was administered concurrently during radiotherapy. Radiation doses were 54 to 69 Gy (median 60 Gy). In those enrolled through January 2000, docetaxel 40 mg/m 2 was administered biweekly (once every two weeks), with subsequent dose adjustments based on tolerance and bone marrow and liver function. Beginning in February 2000, a weekly docetaxel schedule was used instead. This new regimen was based on data suggesting reduced myelosuppression with this regimen. The weekly dose rate was 20 mg/m 2, with dose reductions for impaired organ function. Results: All patients were evaluated for toxicity and response and a total of 40 irradiated sites were evaluated for local response. The overall response rate of irradiated sites was 95% and the CR rate was 68%. CR and PR were achieved in 40%, 37% of patients, respectively. Acute toxicities were tolerated by most patients: 17% had Grade 3-4 neutropenia, 6% had Grade 3-4 radiation dermatitis, and 3% had Grade 3-4 pneumonitis. Conclusion: The combination of docetaxel with radiotherapy is an active and safe regimen in patients with inoperable advanced or recurrent breast cancer. We determined the recommended dose of docetaxel with concomitant radiotherpy to be 20 mg/m 2 weekly for a Phase II study. Further study is necessary to assess the impact of this treatment on long-term outcome.

Original languageEnglish
Pages (from-to)268-274
Number of pages7
JournalBreast Cancer
Volume10
Issue number3
DOIs
Publication statusPublished - Jul 2002

Fingerprint

docetaxel
Radiotherapy
Breast Neoplasms
Radiodermatitis
Neutropenia
Pneumonia
Appointments and Schedules

Keywords

  • Breast cancer
  • Concurrent chemotherapy
  • Docetaxel
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Karasawa, K., Katsui, K., Seki, K., Kohno, M., Hanyu, N., Nasu, S., ... Takahashi, I. (2002). Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer, 10(3), 268-274. https://doi.org/10.1007/BF02966728

Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. / Karasawa, Kumiko; Katsui, Kuniaki; Seki, Kaori; Kohno, Mari; Hanyu, Nahoko; Nasu, Sachiko; Muramatsu, Hiroyuki; Maebayashi, Katsuya; Mitsuhashi, Norio; Haga, Shunsuke; Kimura, Tsunehito; Takahashi, Isamu.

In: Breast Cancer, Vol. 10, No. 3, 07.2002, p. 268-274.

Research output: Contribution to journalArticle

Karasawa, K, Katsui, K, Seki, K, Kohno, M, Hanyu, N, Nasu, S, Muramatsu, H, Maebayashi, K, Mitsuhashi, N, Haga, S, Kimura, T & Takahashi, I 2002, 'Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer', Breast Cancer, vol. 10, no. 3, pp. 268-274. https://doi.org/10.1007/BF02966728
Karasawa, Kumiko ; Katsui, Kuniaki ; Seki, Kaori ; Kohno, Mari ; Hanyu, Nahoko ; Nasu, Sachiko ; Muramatsu, Hiroyuki ; Maebayashi, Katsuya ; Mitsuhashi, Norio ; Haga, Shunsuke ; Kimura, Tsunehito ; Takahashi, Isamu. / Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. In: Breast Cancer. 2002 ; Vol. 10, No. 3. pp. 268-274.
@article{14150f298971413a95d3be6d5cbb1d17,
title = "Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer",
abstract = "Background: Docetaxel has shown remarkable radiosensitizing properties in vitro. In this study we investigated whether the addition of docetaxel to radiotherapy enhanced tumor response in patients with advanced or recurrent breast cancer. Methods: A total of 35 patients were enrolled in this study. Docetaxel was administered concurrently during radiotherapy. Radiation doses were 54 to 69 Gy (median 60 Gy). In those enrolled through January 2000, docetaxel 40 mg/m 2 was administered biweekly (once every two weeks), with subsequent dose adjustments based on tolerance and bone marrow and liver function. Beginning in February 2000, a weekly docetaxel schedule was used instead. This new regimen was based on data suggesting reduced myelosuppression with this regimen. The weekly dose rate was 20 mg/m 2, with dose reductions for impaired organ function. Results: All patients were evaluated for toxicity and response and a total of 40 irradiated sites were evaluated for local response. The overall response rate of irradiated sites was 95{\%} and the CR rate was 68{\%}. CR and PR were achieved in 40{\%}, 37{\%} of patients, respectively. Acute toxicities were tolerated by most patients: 17{\%} had Grade 3-4 neutropenia, 6{\%} had Grade 3-4 radiation dermatitis, and 3{\%} had Grade 3-4 pneumonitis. Conclusion: The combination of docetaxel with radiotherapy is an active and safe regimen in patients with inoperable advanced or recurrent breast cancer. We determined the recommended dose of docetaxel with concomitant radiotherpy to be 20 mg/m 2 weekly for a Phase II study. Further study is necessary to assess the impact of this treatment on long-term outcome.",
keywords = "Breast cancer, Concurrent chemotherapy, Docetaxel, Radiotherapy",
author = "Kumiko Karasawa and Kuniaki Katsui and Kaori Seki and Mari Kohno and Nahoko Hanyu and Sachiko Nasu and Hiroyuki Muramatsu and Katsuya Maebayashi and Norio Mitsuhashi and Shunsuke Haga and Tsunehito Kimura and Isamu Takahashi",
year = "2002",
month = "7",
doi = "10.1007/BF02966728",
language = "English",
volume = "10",
pages = "268--274",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer

AU - Karasawa, Kumiko

AU - Katsui, Kuniaki

AU - Seki, Kaori

AU - Kohno, Mari

AU - Hanyu, Nahoko

AU - Nasu, Sachiko

AU - Muramatsu, Hiroyuki

AU - Maebayashi, Katsuya

AU - Mitsuhashi, Norio

AU - Haga, Shunsuke

AU - Kimura, Tsunehito

AU - Takahashi, Isamu

PY - 2002/7

Y1 - 2002/7

N2 - Background: Docetaxel has shown remarkable radiosensitizing properties in vitro. In this study we investigated whether the addition of docetaxel to radiotherapy enhanced tumor response in patients with advanced or recurrent breast cancer. Methods: A total of 35 patients were enrolled in this study. Docetaxel was administered concurrently during radiotherapy. Radiation doses were 54 to 69 Gy (median 60 Gy). In those enrolled through January 2000, docetaxel 40 mg/m 2 was administered biweekly (once every two weeks), with subsequent dose adjustments based on tolerance and bone marrow and liver function. Beginning in February 2000, a weekly docetaxel schedule was used instead. This new regimen was based on data suggesting reduced myelosuppression with this regimen. The weekly dose rate was 20 mg/m 2, with dose reductions for impaired organ function. Results: All patients were evaluated for toxicity and response and a total of 40 irradiated sites were evaluated for local response. The overall response rate of irradiated sites was 95% and the CR rate was 68%. CR and PR were achieved in 40%, 37% of patients, respectively. Acute toxicities were tolerated by most patients: 17% had Grade 3-4 neutropenia, 6% had Grade 3-4 radiation dermatitis, and 3% had Grade 3-4 pneumonitis. Conclusion: The combination of docetaxel with radiotherapy is an active and safe regimen in patients with inoperable advanced or recurrent breast cancer. We determined the recommended dose of docetaxel with concomitant radiotherpy to be 20 mg/m 2 weekly for a Phase II study. Further study is necessary to assess the impact of this treatment on long-term outcome.

AB - Background: Docetaxel has shown remarkable radiosensitizing properties in vitro. In this study we investigated whether the addition of docetaxel to radiotherapy enhanced tumor response in patients with advanced or recurrent breast cancer. Methods: A total of 35 patients were enrolled in this study. Docetaxel was administered concurrently during radiotherapy. Radiation doses were 54 to 69 Gy (median 60 Gy). In those enrolled through January 2000, docetaxel 40 mg/m 2 was administered biweekly (once every two weeks), with subsequent dose adjustments based on tolerance and bone marrow and liver function. Beginning in February 2000, a weekly docetaxel schedule was used instead. This new regimen was based on data suggesting reduced myelosuppression with this regimen. The weekly dose rate was 20 mg/m 2, with dose reductions for impaired organ function. Results: All patients were evaluated for toxicity and response and a total of 40 irradiated sites were evaluated for local response. The overall response rate of irradiated sites was 95% and the CR rate was 68%. CR and PR were achieved in 40%, 37% of patients, respectively. Acute toxicities were tolerated by most patients: 17% had Grade 3-4 neutropenia, 6% had Grade 3-4 radiation dermatitis, and 3% had Grade 3-4 pneumonitis. Conclusion: The combination of docetaxel with radiotherapy is an active and safe regimen in patients with inoperable advanced or recurrent breast cancer. We determined the recommended dose of docetaxel with concomitant radiotherpy to be 20 mg/m 2 weekly for a Phase II study. Further study is necessary to assess the impact of this treatment on long-term outcome.

KW - Breast cancer

KW - Concurrent chemotherapy

KW - Docetaxel

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=4644315001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644315001&partnerID=8YFLogxK

U2 - 10.1007/BF02966728

DO - 10.1007/BF02966728

M3 - Article

VL - 10

SP - 268

EP - 274

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 3

ER -